UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

ofNovember ~~the~~4, ~~Securities Exchange Act of 1934~~2025

October 10, 2025

Date of Report (date of earliest event reported)

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware		~~000-50679~~	000-50679	~~77-0487658~~					77-0487658
(State or other jurisdiction of incorporation)		~~(Commission File Number)~~	(Commission File Number)	~~(I.R.S. EmployerIdentification No.)~~					(I.R.S. Employer Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065 ~~(Address of Principal Executive Offices) (Zip Code)~~

(~~650)~~Address ~~327-3270~~of ~~Registrant’s~~Principal ~~telephone~~Executive ~~number,~~Offices) ~~including~~(Zip ~~area code~~Code)

(650) 327-3270

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol(s)~~	Trading Symbol(s)	~~Name of each exchange on which registered~~		Name of each exchange on which registered
Common Stock, $0.001 par value		~~CORT~~	CORT	~~The Nasdaq Stock Market~~		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~☐ ~~1.02. Termination of a Material Definitive Agreement.~~

OnItem ~~October 10, 2025, Corcept Therapeutics Incorporated (the “Company”) delivered to Optime Care, Inc~~2.02. ~~(“Optime”)~~Results ~~a notice~~ of ~~termination~~Operations ~~of that certain Distribution Services Agreement, dated August 4, 2017, as amended~~ and ~~restated~~Financial ~~on April 1, 2024, by and between Optime and the Company (the “Agreement”), effective as of January 8, 2026~~Condition.

AsItem previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym® and the Company’s authorized generic mifepristone medication (the “Medications”)7.01 ~~Optime~~Regulation ~~provided~~FD ~~services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and reporting (“Pharmacy Services”)~~Disclosure. Effective April 1, 2024, the Company extended the Agreement with Optime through March 31, 2027, with automatic renewal for successive three-year terms. On June 17, 2025, the Company notified Optime that, pursuant to the Company’s rights under Section 18.5 of the Agreement, Optime would cease to be the exclusive provider of Pharmacy Services with respect to the Medications, effective September 15, 2025.

~~The~~On ~~Agreement~~November 4, ~~was subject to customary termination provisions~~2025, ~~including~~Corcept ~~the~~Therapeutics ~~right~~Incorporated ~~of Optime to terminate in~~ (the ~~event~~“Company”) ofissued a ~~material~~press ~~breach~~release byannouncing ~~the~~its ~~Company~~financial ~~that~~results for the ~~Company~~quarter ~~does~~ended ~~not~~September 30, ~~cure~~2025 inand a ~~reasonable~~corporate ~~period of time after receiving written notice~~update. The ~~Agreement~~press ~~further~~release ~~provides~~is ~~that~~attached ~~the~~hereto ~~Company~~as ~~has~~Exhibit ~~the~~99.1 ~~right~~and tois ~~terminate~~incorporated ~~the~~herein ~~Agreement~~by ~~for convenience at any time with 90-days advance notice~~reference.

The ~~description~~information ofin this Item 2.02 and Item 7.01 and the ~~Agreement~~information contained in ~~this~~the ~~Current~~press ~~Report~~release onattached ~~Form~~as ~~8-K~~Exhibit ~~(“Form 8-K”)~~99.1 ~~does~~shall not ~~purport~~be todeemed befiled ~~complete~~for ~~and~~purposes isof Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to, the liabilities of that Section or Sections 11 and is12(a)(2) ~~qualified~~of the Securities Act of 1933, as amended. The information in ~~its~~this ~~entirety~~Item by2.02 ~~reference~~and toItem 7.01 and the ~~Agreement,~~information ~~which~~contained in the ~~Company~~press ~~initially~~release ~~filed~~attached as Exhibit 1099.21 tois ~~its~~not ~~Quarterly~~incorporated ~~Report~~by onreference ~~Form~~into ~~10-Q~~any ~~for~~filing with the ~~three~~U.S. ~~months~~Securities ~~ended~~and ~~March 31~~Exchange Commission made by the Company, ~~2024~~whether made before or after the date hereof, ~~filed~~regardless ~~with~~of any general incorporation language in the ~~SEC~~filing onunless ~~May 1,~~specifically ~~2024.~~stated so therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.	Description
Exhibits No.		Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).
99.1		Press Release of Corcept Therapeutics Incorporated, dated November 4, 2025
104.1		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~CORCEPT THERAPEUTICS INCORPORATED~~

CORCEPT THERAPEUTICS INCORPORATED

Date: October 14, 2025

By:

/s/ Atabak Mokari

Date:

November 4, 2025

By:

/s/ Atabak Mokari

Name:

Atabak Mokari

Name: Atabak Mokari

Title:

Chief Financial Officer

Title: Chief Financial Officer

Filing Compare · CORCEPT THERAPEUTICS INC